We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00345202
First Posted: June 27, 2006
Last Update Posted: May 15, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Regional Hospital Holstebro
June 24, 2006
June 27, 2006
May 15, 2008
September 2004
February 2005   (Final data collection date for primary outcome measure)
  • GFR
  • RPF
  • FEna
  • FELi
  • CLna
  • CLli
Same as current
Complete list of historical versions of study NCT00345202 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects
Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects.
We wanted to test the shortterm effects of HMG-CoA reductase inhibition (atorvastatin) on renal hemodynamics, renal tubular function and vasoactive hormones on healthy subjects.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Healthy
Drug: HMG-CoA reductase inhibition (atorvastatin)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
February 2005
February 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Both men and women
  • Age: Between 20-50
  • BMI<30

Exclusion Criteria:

  • Cl. signs or history of disease of heart, lungs, kidneys or endocrine organs.
  • Abnormal lab. tests( haemoglobin, pl. sodium, pl. potassium, pl.creatinine, pl.bilirubin, pl.ALAT, pl. cholesterol, blood glucose)
  • Albuminuria or glucosuria
  • Cancer
  • Art. hypertension
  • Alcohol abuse
  • Med. treatment, except oral contraceptives
  • Pregnancy or breast feeding
  • Blood donation less than 1 month before study
Sexes Eligible for Study: All
20 Years to 50 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT00345202
MED.RES.HOS.2004.02.LP
Not Provided
Not Provided
Not Provided
Not Provided
Regional Hospital Holstebro
Not Provided
Study Chair: Erling B. Pedersen, Professor Holstebro Sygehus
Regional Hospital Holstebro
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP